Analyzing Cytokinetics (NASDAQ:CYTK) & Kiniksa Pharmaceuticals International (NASDAQ:KNSA)

Cytokinetics (NASDAQ:CYTK) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, analyst recommendations, profitability, dividends and risk.

Earnings & Valuation

This table compares Cytokinetics and Kiniksa Pharmaceuticals International”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04 million	89.04	-$784.96 million	($7.22)	-8.73
Kiniksa Pharmaceuticals International	$677.56 million	8.79	$59.01 million	$0.97	78.69

Kiniksa Pharmaceuticals International has higher revenue and earnings than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Cytokinetics has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500.

Profitability

This table compares Cytokinetics and Kiniksa Pharmaceuticals International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-1,321.12%	N/A	-51.01%
Kiniksa Pharmaceuticals International	9.59%	13.65%	10.09%

Institutional and Insider Ownership

53.9% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 2.6% of Cytokinetics shares are held by company insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for Cytokinetics and Kiniksa Pharmaceuticals International, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1	1	18	0	2.85
Kiniksa Pharmaceuticals International	0	2	7	0	2.78

Cytokinetics currently has a consensus target price of $106.00, suggesting a potential upside of 68.26%. Kiniksa Pharmaceuticals International has a consensus target price of $93.14, suggesting a potential upside of 22.03%. Given Cytokinetics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Cytokinetics is more favorable than Kiniksa Pharmaceuticals International.

Summary

Kiniksa Pharmaceuticals International beats Cytokinetics on 9 of the 14 factors compared between the two stocks.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.